As an increasing number of orphan drugs are FDA approved, health care payers, employers, and providers are attempting to strike a balance between patient access to innovative treatments and overall affordability. Precision's Erin Lopata, Christopher Terrone and Ami Gopalan and their co-authors review the results of a PRECISIONvalue and AMCP survey with payer, provider, and employer decision makers about their experiences and activities in the orphan disease space, including tactics to manage affordability of drugs to treat orphan diseases.

LEARN MORE

The Centers for Medicare & Medicaid Services (CMS) announced another evaluation report of the Oncology Care Model (OCM) in January 2021, covering activities and results for performance periods 1 through 5 of 11. Precision's Maureen Hennessey and Elizabeth Oyekan analyze what we've learned so far as they review the key findings and observations of performance periods 1 through 5.

LEARN MORE

We are happy to announce that PRECISIONvalue has made the list of MM&M's Top 100 North American healthcare agencies of 2021!

LEARN MORE

Spurred by CMS’s decision to cover CAR-T cell therapies under Medicare, commercial payers are beginning to systematize approvals for CAR-T treatment as use of these breakthrough cancer therapies is beginning to ramp up. Precision's Dan Danielson weighs in on factors driving authorizations now and what to expect as more CAR-T therapies are approved.

LEARN MORE